JOINT FILING AGREEMENTJoint Filing Agreement • February 11th, 2022 • Buxton Helmsley Group, Inc. • Pharmaceutical preparations
Contract Type FiledFebruary 11th, 2022 Company IndustryIn accordance with Rule 13d-1(k) under the Securities Exchange Act of 1934, as amended, the undersigned agree to the joint filing on behalf of each of them of a statement on Schedule 13D, including all amendments thereto, with respect to the ordinary shares, par value $0.20 per share, of Mallinckrodt plc, and further agree that this Joint Filing Agreement shall be included as an exhibit to the first such joint filing and may, as required, be included as an exhibit to subsequent amendments thereto.
JOINT FILING AGREEMENTJoint Filing Agreement • February 1st, 2022 • Buxton Helmsley Group, Inc. • Pharmaceutical preparations
Contract Type FiledFebruary 1st, 2022 Company IndustryIn accordance with Rule 13d-1(k) under the Securities Exchange Act of 1934, as amended, the undersigned agree to the joint filing on behalf of each of them of a statement on Schedule 13D, including all amendments thereto, with respect to the ordinary shares, par value $0.20 per share, of Mallinckrodt plc, and further agree that this Joint Filing Agreement shall be included as an exhibit to the first such joint filing and may, as required, be included as an exhibit to subsequent amendments thereto.
JOINT FILING AGREEMENTJoint Filing Agreement • January 26th, 2022 • Buxton Helmsley Group, Inc. • Pharmaceutical preparations
Contract Type FiledJanuary 26th, 2022 Company IndustryIn accordance with Rule 13d-1(k) under the Securities Exchange Act of 1934, as amended, the undersigned agree to the joint filing on behalf of each of them of a statement on Schedule 13D, including all amendments thereto, with respect to the ordinary shares, par value $0.20 per share, of Mallinckrodt plc, and further agree that this Joint Filing Agreement shall be included as an exhibit to the first such joint filing and may, as required, be included as an exhibit to subsequent amendments thereto.
JOINT FILING AGREEMENTJoint Filing Agreement • January 24th, 2022 • Buxton Helmsley Group, Inc. • Pharmaceutical preparations
Contract Type FiledJanuary 24th, 2022 Company IndustryIn accordance with Rule 13d-1(k) under the Securities Exchange Act of 1934, as amended, the undersigned agree to the joint filing on behalf of each of them of a statement on Schedule 13D, including all amendments thereto, with respect to the ordinary shares, par value $0.20 per share, of Mallinckrodt plc, and further agree that this Joint Filing Agreement shall be included as an exhibit to the first such joint filing and may, as required, be included as an exhibit to subsequent amendments thereto.
JOINT FILING AGREEMENTJoint Filing Agreement • November 5th, 2021 • Buxton Helmsley Group, Inc. • Pharmaceutical preparations
Contract Type FiledNovember 5th, 2021 Company IndustryIn accordance with Rule 13d-1(k) under the Securities Exchange Act of 1934, as amended, the undersigned agree to the joint filing on behalf of each of them of a statement on Schedule 13D, including all amendments thereto, with respect to the ordinary shares, par value $0.20 per share, of Mallinckrodt plc, and further agree that this Joint Filing Agreement shall be included as an exhibit to the first such joint filing and may, as required, be included as an exhibit to subsequent amendments thereto.
JOINT FILING AGREEMENTJoint Filing Agreement • October 22nd, 2021 • Buxton Helmsley Group, Inc. • Pharmaceutical preparations
Contract Type FiledOctober 22nd, 2021 Company IndustryIn accordance with Rule 13d-1(k) under the Securities Exchange Act of 1934, as amended, the undersigned agree to the joint filing on behalf of each of them of a statement on Schedule 13D, including all amendments thereto, with respect to the ordinary shares, par value $0.20 per share, of Mallinckrodt plc, and further agree that this Joint Filing Agreement shall be included as an exhibit to the first such joint filing and may, as required, be included as an exhibit to subsequent amendments thereto.
JOINT FILING AGREEMENTJoint Filing Agreement • October 15th, 2021 • Buxton Helmsley Group, Inc. • Pharmaceutical preparations
Contract Type FiledOctober 15th, 2021 Company IndustryIn accordance with Rule 13d-1(k) under the Securities Exchange Act of 1934, as amended, the undersigned agree to the joint filing on behalf of each of them of a statement on Schedule 13D, including all amendments thereto, with respect to the ordinary shares, par value $0.20 per share, of Mallinckrodt plc, and further agree that this Joint Filing Agreement shall be included as an exhibit to the first such joint filing and may, as required, be included as an exhibit to subsequent amendments thereto.
JOINT FILING AGREEMENTJoint Filing Agreement • August 3rd, 2021 • Buxton Helmsley Group, Inc. • Pharmaceutical preparations
Contract Type FiledAugust 3rd, 2021 Company IndustryIn accordance with Rule 13d-1(k) under the Securities Exchange Act of 1934, as amended, the undersigned agree to the joint filing on behalf of each of them of a statement on Schedule 13D, including all amendments thereto, with respect to the ordinary shares, par value $0.20 per share, of Mallinckrodt plc, and further agree that this Joint Filing Agreement shall be included as an exhibit to the first such joint filing and may, as required, be included as an exhibit to subsequent amendments thereto.